Skip to main content
. Author manuscript; available in PMC: 2016 Mar 3.
Published in final edited form as: Scand J Rheumatol. 2015 Nov 3;45(2):129–134. doi: 10.3109/03009742.2015.1067713

Figure 2.

Figure 2

Figure 2

A: Affected body surface area (BSA) prior to initiation of treatment (pre-treatment) and at treatment termination (post-treatment) in patients treated with CS alone or with D-Pen plus CS. B: Bar graph showing the averages of clinical response of patients treated with CS alone or with D-Pen plus CS according to treating physician assessment.

Figure 2A. Affected Body Surface Area (BSA) pre and post-treatment.

Figure 2B. Percentage of responders by physician assessment.